Protara Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Protara Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2013 to Q3 2024.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $931K, a 35.7% decline year-over-year.
  • Protara Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $4.67M, a 23% decline year-over-year.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6.09M, a 8.91% decline from 2022.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.69M.
  • Protara Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $943K, a 72.5% decline from 2018.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $4.67M $931K -$516K -35.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $5.19M $1.06M -$554K -34.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $5.74M $1.23M -$349K -22.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $6.09M $1.45M +$22K +1.54% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $6.07M $1.45M +$10K +0.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $6.06M $1.62M -$324K -16.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $6.38M $1.58M -$304K -16.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $6.69M $1.43M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $1.44M -$1.28M -47.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $1.94M -$1.06M -35.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $1.88M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q3 2021 $2.72M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $3M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q4 2019 $943K -$34K -$816K -104% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-20
Q3 2019 $1.76M $96K -$808K -89.4% Jul 1, 2019 Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $2.57M $101K -$821K -89% Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $3.39M $780K -$41K -4.99% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $3.43M $782K +$14K +1.82% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 $3.42M $904K +$157K +21% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $3.26M $922K +$55K +6.34% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $3.2M $821K -$24K -2.84% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $3.23M $768K -$76K -9.01% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 $3.3M $747K +$60K +8.73% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $3.24M $867K -$79K -8.35% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $3.32M $845K -$21K -2.43% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $3.34M $844K +$174K +26% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-13
Q3 2016 $3.17M $687K +$76K +12.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $3.09M $946K +$470K +98.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 $2.62M $866K +$459K +113% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $2.16M $670K +$445K +198% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-14
Q3 2015 $1.72M $611K +$426K +230% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 $1.29M $476K +$444K +1388% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $849K $407K +$390K +2294% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 $459K $225K Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 $185K +$164K +781% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 $32K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 $17K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-13
Q3 2013 $21K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.